Nephrology

Incidence of death from cardiovascular causes was lower in the finerenone group (458 of 3686 patients) compared to the placebo group (519 of 3666 patients).

The new SLE test enhances specificity without sacrificing sensitivity.

The FDA noted the extent of the treatment effect of tenapanor is of unclear clinical significance, despite evidence of efficacy.

The priorities established by a panel of experts are designed to improve efficacy and equity in kidney research and care.

The treatment met all 5 primary efficacy endpoints as part of the ASCEND program.

The FDA Cardiovascular and Renal Drugs Advisory Committee cited concerns over an increase in thrombotic events.

Finerenone was shown to reduce risk for kidney decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure.

Dennis Bruemmer, MD discusses new agents and perspectives on care in treating patients with type 2 diabetes at high risk of CV, renal complications.

Data show event rates varied two-fold across regions, with risk reduction of T2D and CKD events across geographic regions without heterogeneity.

The study shows a reduction in hemoglobin and a reduced risk of hypoglycemia in participants.

Data show a 38% reduction in T2D incidence with dapagliflozin compared to placebo in patients with CKD.

Data show 66% of healthcare professionals reported greater confidence in prescribing SGLT2i, while 55% reported greater confidence in prescribing GLP-1.

eGFR improved by 10.8% and creatinine decreased by 6.8% in patients who received PIT procedures.

Data show consistent benefit of finerenone on kidney and CV outcomes in patients with CKD and T2D, regardless of SGLT-2i use.

Patients with chronic kidney disease reported poor quality of life, particularly in domains related to their condition.

Older age, macroalbuminaria, and high diastolic blood pressure are among some of the risk factors significantly associated with onset of chronic kidney disease.

Baseline eGFR and increasing age were good predictors of eGFR.

There was a notable association between the comorbid population and congestive heart failure exacerbations.

The single 1000 mg dose treats iron deficiency anemia in adult patients.

Bayer has submitted a New Drug Application for the mineralocorticoid receptor antagonist.

More than 40% of the treatment arm of the placebo-controlled trial achieved a complete renal response.

The SGLT2 inhibitor is the first of its class to receive indication for treating kidney outcomes regardless of a patient's diabetes status.

Agency requests additional analyses on the novel mechanism of action on the serum phosphorus treatment for chronic kidney disease patients on dialysis.

A new study on dapagliflozin use finds consistent risk reduction in treatment of patients with higher rates of kidney dysfunction.

Medtronic claims the GI Genius module will help clinicals identify lesions in real time during a colonoscopy.

Many believed radiocontrast exposure could be linked to long-term kidney impairment.

As a multi-systemic disorder, Fabry disease can impact the functions of various organs. As a genetic disorder, Fabry can impact the offsprings, parents, and relatives of the patient. Therefore, its effects are far-reaching.

COVID-19-associated AKI patients had fewer comorbidities compared to AKI patients without the viral infection.

The FDA will consider the approval of the biologics license application next month.

Traditional screenings for kidney allograft rejections can be expensive and invasive, highlighting the need for new methods.